Cost effectiveness and screening interval of lipid screening in Hodgkin's lymphoma survivors

Journal of Clinical Oncology

Volumn 27, Issue 32, 2009, Pages 5383-5389

  Chen, Aileen B ^a   Punglia, Rinaa S ^a   Kuntz, Karen M ^a   Mauch, Peter M ^a   Ng, Andrea K ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PRAVASTATIN; SIMVASTATIN; LIPID;

ADULT; AGED; ARTICLE; CANCER SURVIVOR; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; FEMALE; FOLLOW UP; HEALTH CARE COST; HODGKIN DISEASE; HUMAN; HYPERLIPIDEMIA; INTERMETHOD COMPARISON; LIFE EXPECTANCY; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL LITERATURE; MEDICARE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RISK FACTOR; RISK REDUCTION; SCREENING TEST; SENSITIVITY ANALYSIS; SURVIVAL TIME; UNITED STATES; COST BENEFIT ANALYSIS; ECONOMICS; MASS SCREENING; METHODOLOGY; PROBABILITY; QUALITY OF LIFE; REPRODUCIBILITY; SURVIVAL; SURVIVOR;

ADULT; COHORT STUDIES; COST-BENEFIT ANALYSIS; FEMALE; HODGKIN DISEASE; HUMANS; LIPIDS; MALE; MARKOV CHAINS; MASS SCREENING; QUALITY OF LIFE; REPRODUCIBILITY OF RESULTS; SURVIVAL ANALYSIS; SURVIVORS;

EID: 73949141217     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.22.8460     Document Type: Article

References (51)

1. Kennedy BJ, Fremgen AM, Menck HR: The National Cancer Data Base report on Hodgkin's disease for 1985-1989 and 1990-1994. Cancer 83: 1041-1047, 1998
2. Oza AM, Ganesan TS, Leahy M, et al: Patterns of survival in patients with Hodgkin's disease: Long follow up in a single centre. Ann Oncol 4:385-392, 1993
3. Henry-Amar M, Somers R: Survival outcome after Hodgkin's disease: A report from the international data base on Hodgkin's disease. Semin Oncol 17:758-768, 1990
4. Ng AK, Bernardo MP, Weller E, et al: Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol 20:2101-2108, 2002
5. Hudson MM, Poquette CA, Lee J, et al: Increased mortality after successful treatment for Hodgkin's disease. J Clin Oncol 16:3592-3600, 1998
6. Hancock SL, Hoppe RT: Long-term complications of treatment and causes of mortality after Hodgkin's disease. Semin Radiat Oncol 6:225-242, 1996
7. Carver JR, Shapiro CL, Ng A, et al: American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: Cardiac and pulmonary late effects. J Clin Oncol 25: 3991-4008, 2007
8. Hoppe RT: Hodgkin's disease: Complications of therapy and excess mortality. Ann Oncol 8:115-118, 1997 (suppl 1)
9. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, et al: Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 21:3431-3439, 2003
10. Swerdlow AJ, Higgins CD, Smith P, et al: Myocardial infarction mortality risk after treatment for Hodgkin disease: A collaborative British cohort study. J Natl Cancer Inst 99:206-214, 2007
11. Hancock SL, Tucker MA, Hoppe RT: Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 270:1949-1955, 1993
12. Adams MJ, Lipsitz SR, Colan SD, et al: Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol 22:3139-3148, 2004
13. Hull MC, Morris CG, Pepine CJ, et al: Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. JAMA 290:2831-2837, 2003
14. Lee CK, Aeppli D, Nierengarten ME: The need for long-term surveillance for patients treated with curative radiotherapy for Hodgkin's disease: University of Minnesota experience. Int J Radiat Oncol Biol Phys 48:169-179, 2000
15. Mauch P, Ng A, Aleman B, et al: Report from the Rockefeller Foundation Sponsored International Workshop on Reducing Mortality and Improving Quality of Life in Long-Term Survivors of Hodgkin's Disease: July 9-16, 2003, Bellagio, Italy. Eur J Haematol 75:68-76, 2005 (suppl)
16. Glanzmann C, Kaufmann P, Jenni R, et al: Cardiac risk after mediastinal irradiation for Hodgkin's disease. Radiother Oncol 46:51-62, 1998
17. Glanzmann C, Huguenin P, Lutolf UM, et al: Cardiac lesions after mediastinal irradiation for Hodgkin's disease. Radiother Oncol 30:43-54, 1994
18. Downs JR, Clearfield M, Weis S, et al: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS - Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279: 1615-1622, 1998
19. Shepherd J, Cobbe SM, Ford I, et al: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med 333:1301-1307, 1995
20. Expert Panel on Radiation Oncology-Hodgkin's Working Group: Follow-up of Hodgkin's disease. ACR appropriatenesscriteria.http://www.acr.org/Secondary MainMenuCategories/quality-safety/app-criteria/pdf/ ExpertPanelonRadiationOncologyHodgkinsWorkGroup/FollowUpofHodgkinsDiseaseDoc2. aspx
21. National Comprehensive Cancer Network: National Comprehensive Cancer Network guidelines: Hodgkin disease/lymphoma, 2009. http://www.nccn.org/ professionals/physician-gls/f-guidelines.asp
22. Children's Oncology Group: Long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers, 2008. http://www.guidelines. gov/summary/summary.aspx?ss=15&doc-id=10772&nbr=5600
23. Sonnenberg FA, Beck JR: Markov models in medical decision making: A practical guide. Med Decis Making 13:322-338, 1993
24. Torrance GW: Measurement of health state utilities for economic appraisal. J Health Econ 5:1-30, 1986
25. Shepherd J, Blauw GJ, Murphy MB, et al: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 360:1623-1630, 2002
26. Weinstein MC, Siegel JE, Gold MR, et al: Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 276: 1253-1258, 1996
27. Ng A, Diller L, Recklitis C, et al: A questionnaire study on long-term survivors of Hodgkin's disease (HD). Presented at the Rockefeller Foundation Sponsored International Workshop on Reducing Mortality and Improving Quality of Life in Long-Term Survivors of Hodgkin's Disease, Bellagio, Italy, July 9-16, 2003
28. Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al: Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 109:1878-1886, 2007
29. National Center for Health Statistics:USlife tables. http://www.cdc.gov/ nchs/data/dvs/LCWK1-2000.pdf
30. National Center for Health Statistics: National Health and Nutrition Examination Survey data. http://www.cdc.gov/nchs/nhanes/nhanes-questionnaires. htm
31. Wilson PW, D'Agostino RB, Levy D, et al: Prediction of coronary heart disease using risk factor categories. Circulation 97:1837-1847, 1998
32. Goldberg RJ, McCormick D, Gurwitz JH, et al: Age-related trends in short- and long-term survival after acute myocardial infarction: A 20-year population-based perspective (1975-1995). Am J Cardiol 82:1311-1317, 1998
33. Fryback DG, Dasbach EJ, Klein R, et al: The Beaver Dam Health Outcomes Study: Initial catalog of health-state quality factors. Med Decis Making 13:89-102, 1993
34. US Department of Health and Human Services: Centers for Medicare and Medicaid Services fee schedules, 2006. http://www.cms.hhs.gov/Fee ScheduleGenInfo/
35. 2007 Red Book. Montvale, NJ, Thomson Healthcare, 2007
36. US Department of Labor, Bureau of Labor Statistics: Consumer price index: Medical care component. http://data.bls.gov/cgi-bin/surveymost?cu
37. Parke-Davis: Lipitor (package insert). Morris Plains, NJ, Parke-Davis, 2002
38. Russell MW, Huse DM, Drowns S, et al: Direct medical costs of coronary artery disease in the United States. Am J Cardiol 81:1110-1115, 1998
39. Etemad LR, McCollam PL: Total first-year costs of acute coronary syndrome in a managed care setting. J Manag Care Pharm 11:300-306, 2005
40. Smith TL, Melfi CA, Kesterson JA, et al: Direct medical charges associated with myocardial infarction in patients with and without diabetes. Med Care 37:AS4-AS11, 1999 (suppl)
41. Bundorf MK, Schulman KA, Stafford JA, et al: Impact of managed care on the treatment, costs, and outcomes of fee-for-service Medicare patients with acute myocardial infarction. Health Serv Res 39:131-152, 2004
42. Eisenstein EL, Shaw LK, Anstrom KJ, et al: Assessing the clinical and economic burden of coronary artery disease: 1986-1998. Med Care 39:824-835, 2001
43. Prosser LA, Stinnett AA, Goldman PA, et al: Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Ann Intern Med 132:769-779, 2000
44. Goldman L, Weinstein MC, Goldman PA, et al: Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA 265:1145-1151, 1991
45. Berg AO, Atkins D: U.S. Preventive Services Task Force: Screening for lipid disorders in adults - Recommendations and rationale. Am J Nurs 102:91, 93, 95, 2002
46. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001
47. Genest J, Frohlich J, Fodor G, et al: Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: Summary of the 2003 update. CMAJ 169:921-924, 2003
48. American College of Physicians: Guidelines for using serum cholesterol, high-density lipoprotein cholesterol, and triglyceride levels as screening tests for preventing coronary heart disease in adults: Part 1. Ann Intern Med 124:515-517, 1996
49. Grundy SM, Cleeman JI, Merz CN, et al: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110:227-239, 2004
50. Aviles A, Neri N, Nambo JM, et al: Late cardiac toxicity secondary to treatment in Hodgkin's disease: A study comparing doxorubicin, epirubicin and mitoxantrone in combined therapy. Leuk Lymphoma 46:1023-1028, 2005
51. Myrehaug S, Pintilie M, Tsang R, et al: Cardiac morbidity following modern treatment for Hodgkin lymphoma: Supra-additive cardiotoxicity of doxorubicin and radiation therapy. Leuk Lymphoma 49: 1486-1493, 2008